Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A7WO
|
|||
| Former ID |
DIB014739
|
|||
| Drug Name |
NT-501
|
|||
| Synonyms |
NTC-201E; CNTF cell implant (ECT), Neurotech; CNTF ophthalmic cell implant (retinitis pigmentosa), Neurotech; Cell implant (ciliary neurotrophic factor), Neurotech; Cell implant (retinitis pigmentosa, ECT), Neurotech
Click to Show/Hide
|
|||
| Indication | Ocular inflammation [ICD-11: 9C61.24; ICD-10: H40.4; ICD-9: 370.33] | Phase 2/3 | [1] | |
| Retinitis pigmentosa [ICD-11: 9B70; ICD-10: H35.5] | Phase 2/3 | [2] | ||
| Macular telangiectasia type 2 [ICD-11: 9B75.3] | Phase 2 | [2] | ||
| Company |
Amgen Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ciliary neurotrophic factor receptor alpha (CNTFR) | Target Info | Modulator | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| WikiPathways | Adipogenesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00447980) A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of Neurotech. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.